Learn why this is the perfect time of the year to mobilize your board members.
Glenn S. Demby
Posts by the Author
A decline in COVID-19 testing demand, along with a challenging economy, made for a difficult quarter for diagnostics companies.
Having twice failed to disrupt health care, Amazon opts for a different strategy this time around—and it may just work.
A high volume of FDA approvals for new tests and diagnostic products made up for the relatively low number of approvals in the EU.
Automating travel and expense significantly improves performance, but adding mobility takes such improvements to a much higher level.
The recent FDA approval of an OTC test shows that COVID-19 saliva testing may be poised for bigger and better things in the years ahead.
Though only seven transactions were announced or closed in November, two were billion-dollar deals.
The company’s third attempt at shaking up the healthcare industry, Amazon Clinic, might just prove the charm.
M&A deals in the diagnostics industry have been lower in number, but higher in impact in recent months.
Key cases over the past month were the usual FCA-related fare, apart from a dismissed sex discrimination case.